Toxidermies aux médicaments du xxie siècle

New drugs, especially biotherapies, are increasingly used for a rapidly expanding number of inflammatory and neoplastic diseases. Among these treatments, cytokines, monoclonal antibodies, anti-TNF, inhibitors of tyrosine kinase, inhibitors of epidermal growth factors receptors can induce adverse cutaneous effects. These patients need early and appropriate dermatological management. Other new drugs, such as voriconazole, lamotrigine, bupropion… are also a possible cause of skin reactions.